| Literature DB >> 31694283 |
Simayijiang Aimaiti1, Yohei Saito1, Shuichi Fukuyoshi1, Masuo Goto2, Katsunori Miyake3, David J Newman4, Barry R O'Keefe5,6, Kuo-Hsiung Lee2,7, Kyoko Nakagawa-Goto1,2.
Abstract
Seven new butanolides,Entities:
Keywords: Hernandia nymphaeifolia; antiproliferative activity; butanolides; lignan glycosides
Mesh:
Substances:
Year: 2019 PMID: 31694283 PMCID: PMC6864620 DOI: 10.3390/molecules24214005
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Isolated compounds (1−20) from H. nymphaeifolia.
1H NMR Spectroscopic data of compounds 1−7.
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|---|
| Position | |||||||
| 1 | 2.15 s | ||||||
| 3 | 5.26 brs | 5.26 brs | 5.26 brd (5.6) | 5.11 m | 5.10 brd (7.3) | 4.82 brs | 4.89 d (4.2) |
| 5a | 4.72 dd (2.8, 1.4) | 4.72 dd (2.8, 1.4) | 4.72 dd (2.8, 1.4) | 4.67 dd (2.8, 1.4) | 4.66 dd (2.8, 1.4) | 1.62 s | 7.07 t (8.0) |
| 5b | 4.96 dd (2.8, 1.4) | 4.96 dd (2.8, 1.4) | 4.96 dd (2.8, 1.4) | 4.89 dd (2.8, 1.4) | 4.89 dd (2.8, 1.4) | ||
| 6 | 7.09 td (7.8, 2.2) | 7.09 td (7.8, 2.2) | 7.10 td (7.8, 2.2) | 6.69 td (7.8, 2.2) | 6.67 td (7.8, 2.2) | 7.04 td (7.8, 2.2) | 2.34 td (14.8, 8.0) |
| 7 | 2.48 m | 2.48 m | 2.48 m, 2.43 m | 2.78 m | 2.76 m | 2.38 m | 1.50 m |
| 8 | 1.52 m | 1.52 m | 1.53 m | 1.46 m | 1.45 m | 1.52 m | 1.25 mp |
| 9–18 | 1.26 mc | 1.26 me | 1.25 mg | 1.25 mh | 1.25 mj | 1.25 mm | 1.25 mp |
| 19 | 2.00 m | 1.26 me | 1.25 mg | 1.25 mh | 1.25 mj | 2.01 mn | 2.00 mq |
| 20 | 5.36 md | 1.26 me | 1.25 mg | 1.25 mh | 1.25 mj | 5.34 t (4.8)o | 5.34 t (4.8)r |
| 21 | 5.36 md | 1.26 me | 1.25 mg | 2.02 m | 1.25 mj | 5.34 t (4.8)o | 5.34 t (4.8)r |
| 22 | 2.02 m | 1.26 me | 1.25 mg | 5.35 mi | 1.25 mj | 2.01 mn | 2.00 mq |
| 23 | 1.26 mc | 2.00 m | 1.25 mg | 5.35 mi | 2.01 mk | 1.25 mm | 1.25 mp |
| 24 | 1.32 m | 5.36 mf | 1.25 mg | 2.02 | 5.33 ml | 1.31 | 1.25 mp |
| 25 | 0.89 t (6.9) | 5.36 mf | 0.89 br t (7.3) | 1.25 mh | 5.33 ml | 0.89 t (6.0) | 1.31 m |
| 26 | 2.02 m | 1.33 m | 2.01 mk | 0.89 t (6.0) | |||
| 27 | 1.26 me | 0.88 t (6.9) | 1.25 mj | ||||
| 28 | 1.32 m | 1.32 m | |||||
| 29 | 0.89 t (7.3) | 0.87 t (6.9) | |||||
| 2-OH | 2.26 m | ||||||
| 3-OH | 4.00 brs | ||||||
| OCH3 | 3.72 s |
600 MHz, 400 MHz, Overlapping signals.
13C NMR Spectroscopic data in CDCl3 of compounds 1−7.
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|---|
| Position |
|
|
|
|
|
|
|
| 1 | 166.5 | 166.5 | 166.3 | 163.1 | 166.4 | 24.8 | |
| 2 | 127.3 | 127.3 | 127.2 | 127.4 | 127.3 | 125.2 | 206.3 |
| 3 | 66.5 | 66.5 | 66.6 | 68.9 | 68.9 | 70.9 | 73.4 |
| 4 | 157.6 | 157.6 | 157.5 | 160.1 | 160.2 | 100.1 | 129.8 |
| 5 | 91.4 | 91.4 | 91.5 | 90.3 | 90.4 | 26.8 | 149.0 |
| 6 | 150.3 | 150.3 | 150.3 | 151.4 | 151.4 | 151.9 | 28.7 |
| 7 | 29.8 | 29.8 | 29.8 | 29.8 | 29.8 | 30.1 | 29.3 |
| 8 | 28.4 | 28.4 | 28.4–29.6d | 28.4 | 28.4 | 29.5–29.9g | 29.4–30.0h |
| 9–18 | 29.4–30.0 | 29.4–30.0c | 28.4–29.6d | 29.4–30.0e | 29.4–30.0f | 29.5–29.9g | 29.4–30.0h |
| 19 | 27.0 | 29.4–30.0c | 28.4–29.6d | 29.4–30.0e | 29.4–30.0f | 27.0 | 27.2 |
| 20 | 129.8 | 29.4–30.0c | 28.4–29.6d | 29.4–30.0e | 29.4–30.0f | 129.8 | 129.8 |
| 21 | 129.9 | 29.4–30.0c | 28.4–29.6d | 27.0 | 29.4–30.0f | 129.9 | 129.9 |
| 22 | 27.2 | 29.4–30.0c | 28.4–29.6d | 129.8 | 29.4–30.0f | 27.7 | 27.2 |
| 23 | 32.0 | 27.0 | 32.0 | 129.9 | 27.0 | 32.1 | 29.8 |
| 24 | 22.4 | 129.8 | 22.8 | 27.2 | 129.8 | 22.5 | 31.9 |
| 25 | 14.0 | 129.9 | 14.1 | 32.0 | 129.9 | 14.1 | 22.7 |
| 26 | 27.2 | 22.3 | 27.2 | 14.1 | |||
| 27 | 32.0 | 14.0 | 32.0 | ||||
| 28 | 22.4 | 22.4 | |||||
| 29 | 14.0 | 14.0 | |||||
| COO | 166.5 | ||||||
| OCH3 | 52.0 |
150 MHz, 100 MHz, Overlapping signals.
Figure 2Selected HMBC correlations (arrows in red), COSY connectivities (bold lines) for compounds 1−7.
Figure 3Key NOESY (red dashed lines) correlations for compounds 1–7.
Figure 4Experimental and calculated ECD spectra of compounds 6 and 7.
Figure 5EIMS fragmentation of 7.
Figure 6Selected HMBC correlations (arrows in red), COSY connectivities (bold lines) for 8 and 9.
Figure 7Key NOESY correlations (red lines) and Key ROESY correlations (blue lines) for 8 and 9.
Figure 8Experimental ECD spectra of compounds 8 and 9.
1H and 13C NMR Spectroscopic Data of Compounds 8 and 9.
| 8 (CD3OD) | 9 (CD3OD) | |||
|---|---|---|---|---|
| Position |
|
| ||
| 1 | 134.1 | 131.5 | ||
| 2 | 104.6c | 6.52 sd | 112.3 | 7.09 brs |
| 3 | 149.3 | 147.4 | ||
| 4 | 135.9 | 150.5 | ||
| 5 | 149.3 | 120.6 | 7.06 d (8.2) | |
| 6 | 104.6c | 6.52 sd | 121.1 | 6.96 dd (2.2, 8.2) |
| 7 | 85.1 | 4.63 d (7.3) | 74.9 | 4.85 overlap |
| 8 | 53.7 | 1.89 m | 85.9 | 4.36 m |
| 9 | 62.3 | 3.87 m | 62.2 | 3.82 m |
| 3.63 m | 3.47 m | |||
| 1′ | 139.5 | 137.8 | ||
| 2′ | 112.2 | 6.92 d (1.8) | 118.7g | 6.86 brsg |
| 3′ | 150.7 | 149.2 | ||
| 4′ | 147.5 | 118.7g | 6.86 brsg | |
| 5′ | 117.5 | 7.11 d (8.2) | 151.2 | |
| 6′ | 120.9 | 6.82 dd (8.2, 1.8) | 111.3 | 6.97 d (2.2) |
| 7′ | 74..8 | 4.52 d (8.2) | 132.9 | 6.52 d (15.4) |
| 8′ | 50.7 | 2.53 m | 111.3 | 6.27 dd (5.7, 15.4) |
| 9′ | 76.2 | 4.26 dd (9.0, 4.6) | 63.8 | 4.19 d (5.9) |
| 3.92 m | ||||
| 3-OMe | 56.9 | 3.84 se | 56.7 | 3.81 s |
| 5-OMe | 56.8 | 3.84 se | 56.5 | 3.79 s |
| 3′-OMe | 56.7 | 3.83 s | ||
| Glc-1 | 102.7 | 4.84 m | 103.1 | 4.81 d (6.9) |
| Glc-2 | 74.9 | 3.4–3.8 mf | 73.9 | 3.4–3.8 mh |
| Glc-3 | 78.2 | 3.4–3.8 mf | 78.2 | 3.4–3.8 mh |
| Glc-4 | 71.4 | 3.4–3.8 mf | 71.4 | 3.4–3.8 mh |
| Glc-5 | 77.9 | 3.4–3.8 mf | 77.9 | 3.4–3.8 mh |
| Glc-6 | 62.5 | 3.4–3.8 mf | 62.5 | 3.4–3.8 mh |
100 Hz, 400 Hz, – Overlapping signals.
Antiproliferative Activity of the Isolated Compounds.
| Compounds | Cell Lines | ||||
|---|---|---|---|---|---|
| A549 | MDA-MB-231 | MCF-7 | KB | KB-VIN | |
|
| >40 | 22.5 | >40 | 25.7 | 31.7 |
|
| 21.9 | 24.6 | 24.6 | 22.6 | 21.4 |
|
| 35.1 | 35.3 | 35.7 | 32.7 | 21.7 |
|
| 12.5 | 10.8 | 8.8 | 18.6 | 8.8 |
|
| 32.8 | 37.7 | 33.5 | >40 | 8.7 |
|
| 23.2 | 32.9 | 32.8 | 23.2 | 19.9 |
|
| 8.1 | 20.8 | 6.8 | 20.3 | 5.4 |
|
| 5.7 | 8.2 | 8.1 | 12.6 | 5.3 |
|
| 37.8 | >40 | 38.0 | >40 | 8.2 |
|
| >40 | >40 | >40 | >40 | >40 |
| Paclitaxel (nM) | 6.5 | 8.4 | 12.1 | 7.1 | 2213 |
A549 (lung carcinoma), MDA-MB-231 (triple-negative breast cancer), MCF-7 (estrogen receptor-positive & HER2-negative breast cancer), KB (cervical cancer cell line HeLa derivative), KB-VIN (P-gp-overexpressing multidrug-resistant (MDR) subline of KB). Antiproliferative activity expressed as IC50 values for each cell line cultured with compound for 72 h, the concentration of compound that caused 50% reduction relative to untreated cells determined by the SRB assay. IC50 of all compounds were calculated.